Acurian Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

This sponsor was in a crucial race in the diabetes space as it began phase III clinical trials for a new class of drug for type 2 diabetes.

They were also rolling into a crowded field of companies developing competitive compounds. The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to $50 billion by 2022.


Acurian has the most experience in the industry.

We’ve worked in successful trials ranging from diabetic nephropathy to diabetic neuropathy, with diabetics taking specific medications, to diabetics who must have had a CV event.

Acurian has recruited and enrolled thousands of patients for more than 60 pharmaceutical and biotech companies representing over 4,500 research sites.